Previous 10 | Next 10 |
home / stock / jnj / jnj articles
Thursday, Illumina Inc (NASDAQ:ILMN) reported fourth-quarter 2023 sales of $1.12 billion, up 4% Y/Y, beating the consensus of $1.09 ...
CEOs of Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) defended the high prices of their drugs as they ...
Monday, Johnson & Johnson (NYSE:JNJ) announced topline results from the pivotal Phase 3 VIVACITY study of nipocalimab in ad...
Pharmaceutical companies await the U.S. government’s forthcoming proposal, expected this Thursday, outlining substantial discounts for t...
Opioid producer and raw material supplier Johnson & Johnson (NYSE:JNJ) reached a settlement last week in an opioid lawsuit with Washington s...
Tuesday, the FDA announced to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the ...
Tuesday, Johnson & Johnson (NYSE:JNJ) released better-than-expected earnings for its fourth quarter of 2023. It reported quarterly adjusted e...
U.S. stock futures indicate a positive opening on Wednesday, buoyed by strong earnings reports from Netflix, Inc. (NASDAQ:NFLX) and semic...
The CNN Money Fear and Greed index showed a further increase in overall market sentiment, while the index remained in the "Greed" zone on...
News, Short Squeeze, Breakout and More Instantly...
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with tr...
2024-07-18 11:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 05:40:00 ET On July 17, Johnson & Johnson (NYSE: JNJ) announced second-quarter results that gave investors a lot to look forward to. Integration of newly acquired medical technology plus upcoming expansions of patent-protected medicines will help push the healthcare c...